Busulfan

• CAT Number: A000926
• CAS Number: 55-98-1
• Molecular Formula: C6H14O6S2
• Molecular Weight: 246.30
• Purity: ≥95%
• Synonyms: 55-98-1; Myleran; Busulphan; Sulphabutin; Leucosulfan
• Target: DNA Alkylating
• Solubility: >12.3mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-methylsulfonyloxybutyl methanesulfonate
• InChI: InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
• InChIKey: COVZYZSDYWQREU-UHFFFAOYSA-N
• SMILES: CS(=O)(=O)OCCCCOS(=O)(=O)C

Busulfan（Cat No.:A000926）is an alkylating agent commonly used in chemotherapy, particularly for treating chronic myelogenous leukemia (CML) and as part of conditioning regimens before bone marrow transplants. It works by cross-linking DNA strands, inhibiting DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells. Busulfan is highly effective at suppressing bone marrow function, making it valuable in hematopoietic stem cell transplants. Due to its potent cytotoxic effects, careful monitoring is required to manage potential side effects, including myelosuppression and long-term toxicity.

Reference

1: Faulkner L, Uderzo C, Khalid S, Marwah P, Soni R, Yaqub N, Amanat S, Fatima I,
Gilani SK, Zahra T, Ramprakash S, Gooneratne L, Dissanayake R, Williams S,
Rathnayake W, Srinivas R, Sedai A, Kumari A, Parmar L, Dhanya R, Agarwal RK. ATG
vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow
transplantation for thalassemia. Blood Adv. 2017 May 11;1(13):792-801. doi:
10.1182/bloodadvances.2016004119. eCollection 2017 May 23. PubMed PMID: 29296723;
PubMed Central PMCID: PMC5727808.

2: Cui Y, Ren L, Li B, Fang J, Zhai Y, He X, Du E, Miao Y, Hua J, Peng S.
Melatonin Relieves Busulfan-Induced Spermatogonial Stem Cell Apoptosis of Mouse
Testis by Inhibiting Endoplasmic Reticulum Stress. Cell Physiol Biochem. 2017 Dec
18;44(6):2407-2421. doi: 10.1159/000486165. [Epub ahead of print] PubMed PMID:
29268276.

3: Farhan S, Bazydlo M, Neme K, Mikulandric N, Peres E, Janakiraman N. Chimerism
in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and
without Busulfan Pharmacokinetics versus BuCy. Adv Hematol. 2017;2017:8690416.
doi: 10.1155/2017/8690416. Epub 2017 Nov 8. PubMed PMID: 29250116; PubMed Central
PMCID: PMC5698787.

4: Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G, Socié G,
Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohty M, Nagler A.
Intravenous Busulfan Compared with Treosulfan- Based Conditioning for Allogeneic
Stem-Cell Transplantation in Acute Myeloid Leukemia. a Study on Behalf of the
Acute Leukemia Working Party of EBMT. Biol Blood Marrow Transplant. 2017 Dec 13.
pii: S1083-8791(17)31680-4. doi: 10.1016/j.bbmt.2017.12.776. [Epub ahead of
print] PubMed PMID: 29247780.

5: Brooks KM, Jarosinski P, Hughes T, Kang E, Shah NN, Gall JBL, Hickstein DD, De
Ravin SS, George JM, Kumar P. Test Dose Pharmacokinetics in Pediatric Patients
Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell
Transplant: A Reliable Approach? J Clin Pharmacol. 2017 Dec 14. doi:
10.1002/jcph.1049. [Epub ahead of print] PubMed PMID: 29238995.

6: Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L,
Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius
R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt
H, Krajinovic M. GSTA1 diplotypes affect busulfan clearance and toxicity in
children undergoing allogeneic hematopoietic stem cell transplantation: a
multicenter study. Oncotarget. 2017 Aug 27;8(53):90852-90867. doi:
10.18632/oncotarget.20310. eCollection 2017 Oct 31. PubMed PMID: 29207608; PubMed
Central PMCID: PMC5710889.

7: Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ,
Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP,
Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin
R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the
CIBMTR. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant
Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow
Transplant. 2017 Dec 25. pii: S1083-8791(17)30872-8. doi:
10.1016/j.bbmt.2017.11.025. [Epub ahead of print] PubMed PMID: 29197676.

8: Eva C, Chakradhara Rao Satyanarayana U, Denis M, Melanie K, Fabienne DL,
Rodolfo LP, Yves C, Christina P, Youssef D, Marc A. Therapeutic Drug Monitoring
of Busulfan for The Management of Pediatric Patients: Cross-Validation of Methods
And Long-Term Performance. Ther Drug Monit. 2017 Nov 15. doi:
10.1097/FTD.0000000000000468. [Epub ahead of print] PubMed PMID: 29189665.

9: Chobisa D, Patel K, Monpara J, Patel M, Vavia P. Development and
characterization of an organic solvent free, proliposomal formulation of Busulfan
using quality by design approach. Int J Pharm. 2018 Jan 15;535(1-2):360-370. doi:
10.1016/j.ijpharm.2017.11.007. Epub 2017 Nov 7. PubMed PMID: 29126906.

10: Guichard N, Bonnabry P, Rudaz S, Fleury-Souverain S. Stability of busulfan
solutions in polypropylene syringes and infusion bags as determined with an
original assay. Am J Health Syst Pharm. 2017 Nov 15;74(22):1887-1894. doi:
10.2146/ajhp160516. PubMed PMID: 29118046.